260 related articles for article (PubMed ID: 33796147)
1. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K;
J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177
[TBL] [Abstract][Full Text] [Related]
4. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
5. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
7. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab: A Review in Generalized Myasthenia Gravis.
Dhillon S
Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
[TBL] [Abstract][Full Text] [Related]
10. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.
Jacob S; Murai H; Utsugisawa K; Nowak RJ; Wiendl H; Fujita KP; O'Brien F; Howard JF
Ther Adv Neurol Disord; 2020; 13():1756286420911784. PubMed ID: 32426038
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study.
Nowak RJ; Muppidi S; Beydoun SR; O'Brien FL; Yountz M; Howard JF
Front Neurol; 2020; 11():556104. PubMed ID: 33329303
[No Abstract] [Full Text] [Related]
13. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
[TBL] [Abstract][Full Text] [Related]
14. Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
Mantegazza R; O'Brien FL; Yountz M; Howard JF;
Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
18. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.
Oyama M; Okada K; Masuda M; Shimizu Y; Yokoyama K; Uzawa A; Kawaguchi N; Ikeguchi R; Hoshino Y; Hatano T; Ozawa Y; Nakahara J; Aizawa H; Kitagawa K; Hattori N; Kuwabara S; Murai H; Suzuki S
Ther Adv Neurol Disord; 2020; 13():1756286420904207. PubMed ID: 32215054
[TBL] [Abstract][Full Text] [Related]
19. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Suh J; Clarke V; Amato AA; Guidon AC
Muscle Nerve; 2022 Sep; 66(3):348-353. PubMed ID: 35684980
[TBL] [Abstract][Full Text] [Related]
20. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
